Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-05 4:01 pm Sale | 2023-12-31 | 13G | Xilio Therapeutics, Inc. XLO | Octagon Capital Advisors LP | 1,785,000 6.480% | -640,000 (-26.39%) | Filing History |
| 2023-04-10 4:57 pm Purchase | 2023-03-30 | 13G | Xilio Therapeutics, Inc. XLO | MRL Ventures Fund LLC | 1,483,414 5.400% | 1,483,414 (New Position) | Filing History |
| 2023-02-09 08:14 am Sale | 2023-02-09 | 13G | Xilio Therapeutics, Inc. XLO | FMR LLC | 1,907,671 6.944% | -662,599 (-25.78%) | Filing History |
| 2023-01-25 4:01 pm Purchase | 2022-12-31 | 13G | Xilio Therapeutics, Inc. XLO | Octagon Capital Advisors LP | 2,425,000 8.830% | 2,425,000 (New Position) | Filing History |
| 2022-12-29 5:24 pm Sale | 2022-12-29 | 13G | Xilio Therapeutics, Inc. XLO | Deerfield Mgmt, L.P. | 0 0.000% | -2,154,061 (Position Closed) | Filing History |
| 2022-11-14 4:43 pm Sale | 2022-11-14 | 13G | Xilio Therapeutics, Inc. XLO | RA Capital Management, L.P. | 0 0.000% | -2,002,217 (Position Closed) | Filing History |
| 2022-02-14 4:11 pm Purchase | 2021-12-31 | 13G | Xilio Therapeutics, Inc. XLO | RA Capital Management, L.P. | 2,002,217 7.300% | 469,450 (+30.63%) | Filing History |
| 2022-02-14 06:42 am Unchanged | 2021-12-31 | 13G | Xilio Therapeutics, Inc. XLO | Bain Capital Life Sciences Fund II, L.P. | 1,348,682 4.900% | 0 (Unchanged) | Filing History |
| 2022-02-11 4:14 pm Sale | 2021-12-31 | 13G | Xilio Therapeutics, Inc. XLO | Deerfield Mgmt, L.P. | 2,154,061 7.840% | -133,883 (-5.85%) | Filing History |
| 2022-02-09 10:04 am Sale | 2022-02-08 | 13G | Xilio Therapeutics, Inc. XLO | FMR LLC | 2,570,270 9.357% | -87,400 (-3.29%) | Filing History |
| 2022-01-14 06:07 am Purchase | 2021-12-31 | 13G | Xilio Therapeutics, Inc. XLO | Takeda Pharmaceutical Company Limited | 1,475,121 5.370% | 1,475,121 (New Position) | Filing History |
| 2021-11-05 5:16 pm Purchase | 2021-10-26 | 13G | Xilio Therapeutics, Inc. XLO | Bain Capital Life Sciences Fund II, L.P. | 1,348,682 5.100% | 1,348,682 (New Position) | Filing History |
| 2021-11-05 4:43 pm Purchase | 2021-10-26 | 13G | Xilio Therapeutics, Inc. XLO | Atlas Venture Fund XI, L.P. | 2,023,402 7.600% | 2,023,402 (New Position) | Filing History |
| 2021-11-05 4:34 pm Purchase | 2021-10-22 | 13G | Xilio Therapeutics, Inc. XLO | RA Capital Management, L.P. | 1,532,767 5.700% | 1,532,767 (New Position) | Filing History |
| 2021-11-05 12:54 pm Purchase | 2021-10-26 | 13D | Xilio Therapeutics, Inc. XLO | RiverVest Venture Fund IV L.P. | 1,441,444 5.400% | 1,441,444 (New Position) | Filing History |
| 2021-11-04 09:15 am Purchase | 2021-11-04 | 13G | Xilio Therapeutics, Inc. XLO | FMR LLC | 2,657,670 9.966% | 2,657,670 (New Position) | Filing History |
| 2021-11-03 4:19 pm Purchase | 2021-10-26 | 13D | Xilio Therapeutics, Inc. XLO | SV7 Impact Medicine Fund LP | 1,613,632 6.050% | 1,613,632 (New Position) | Filing History |
| 2021-10-26 7:35 pm Purchase | 2021-10-26 | 13G | Xilio Therapeutics, Inc. XLO | Deerfield Mgmt, L.P. | 2,287,944 8.580% | 2,287,944 (New Position) | Filing History |